Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Personalis, Inc.PSNL · Entity 4572 | Director | May 12, 2026 | May 14, 2026 |
| QuidelOrtho CorpQDEL · Entity 4986 | Director | June 25, 2026 | June 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Personalis, Inc.
Report date May 12, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,250 |
Reported balance
After 2026-05-12 transaction · row 1
1 source rowRow 1 · 2026-05-12 · Grant · Acquired 6,250 · Balance 6,250 F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 100% of the shares subject to the RSU shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the Company's 2019 Equity Incentive Plan (the "2019 Plan")) through the vesting date. In the event of a Change in Control (as defined in the 2019 Plan), the shares underlying the RSU shall vest immediately prior to the effectiveness of such Change in Control. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.04 · Expires 2036-05-12 | Direct | 37,500 |
Reported balance
After 2026-05-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-12 · Grant · Acquired 37,500 · Balance 37,500 F2: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the 2019 Plan) through the vesting date. In the event of a Change in Control (as defined in the 2019 Plan), the shares underlying the option shall vest and become exercisable immediately prior to the effectiveness of such Change in Control. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 100% of the shares subject to the RSU shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the Company's 2019 Equity Incentive Plan (the "2019 Plan")) through the vesting date. In the event of a Change in Control (as defined in the 2019 Plan), the shares underlying the RSU shall vest immediately prior to the effectiveness of such Change in Control.
F2: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the 2019 Plan) through the vesting date. In the event of a Change in Control (as defined in the 2019 Plan), the shares underlying the option shall vest and become exercisable immediately prior to the effectiveness of such Change in Control.
QuidelOrtho Corp
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock Units (Equity Grant)SEC Table II · derivative / convertible security | Direct | 15,532 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 15,532 · Balance 15,532 F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2: The restricted stock units will vest on June 25, 2027. |
| Restricted Stock Units (Converted)SEC Table II · derivative / convertible security | Direct | 6,656 |
Reported balance
After 2026-06-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-25 · Grant · Acquired 6,656 · Balance 6,656 F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4: 1,664 shares vested on June 25, 2026, 1,664 shares will vest on September 25, 2026, 1,664 shares will vest on December 25, 2026, and 1,664 shares will vest on March 25, 2027. |
| Restricted Stock Units (Premium)SEC Table II · derivative / convertible security | Direct | 1,997 |
Reported balance
After 2026-06-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-25 · Grant · Acquired 1,997 · Balance 1,997 F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2: The restricted stock units will vest on June 25, 2027. F3: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.
F2: The restricted stock units will vest on June 25, 2027.
F3: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule.
F4: 1,664 shares vested on June 25, 2026, 1,664 shares will vest on September 25, 2026, 1,664 shares will vest on December 25, 2026, and 1,664 shares will vest on March 25, 2027.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Evoke Pharma Inc
Report date December 17, 2025 · Filed December 17, 2025
Section 16 reporting ended · disclosed 2025-12-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.41 | Direct | 0 |
Reported balance
After 2025-12-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-17 · Disposition to issuer · Disposed 1,187 · Balance 0 F1: In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.45 | Direct | 0 |
Reported balance
After 2025-12-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-17 · Disposition to issuer · Disposed 5,833 · Balance 0 F1: In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 | Direct | 0 |
Reported balance
After 2025-12-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-17 · Disposition to issuer · Disposed 1,187 · Balance 0 F1: In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
QUIDEL CORP /DE/
Report date May 27, 2022 · Filed June 01, 2022
Section 16 reporting ended · disclosed 2022-06-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 1
1 source rowRow 1 · 2022-05-27 · Disposition to issuer · Disposed 18,684 · Balance 0 F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $27.91 · Expires 2024-11-17 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-05-27 · Disposition to issuer · Disposed 3,333 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3: Vested in full. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $22.86 · Expires 2025-05-05 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-05-27 · Disposition to issuer · Disposed 7,021 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3: Vested in full. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $15.74 · Expires 2026-05-17 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-05-27 · Disposition to issuer · Disposed 7,021 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3: Vested in full. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $24.80 · Expires 2027-05-16 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-05-27 · Disposition to issuer · Disposed 5,065 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3: Vested in full. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-05-27 · Disposition to issuer · Disposed 1,050 · Balance 0 F4: Each restricted stock unit represents the right to receive one share of Quidel common stock. F5: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-05-27 · Disposition to issuer · Disposed 315 · Balance 0 F4: Each restricted stock unit represents the right to receive one share of Quidel common stock. F5: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-05-27 · Disposition to issuer · Disposed 328 · Balance 0 F4: Each restricted stock unit represents the right to receive one share of Quidel common stock. F5: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-05-27 · Disposition to issuer · Disposed 98 · Balance 0 F4: Each restricted stock unit represents the right to receive one share of Quidel common stock. F5: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-05-27 · Disposition to issuer · Disposed 512 · Balance 0 F4: Each restricted stock unit represents the right to receive one share of Quidel common stock. F5: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-05-27 · Disposition to issuer · Disposed 153 · Balance 0 F4: Each restricted stock unit represents the right to receive one share of Quidel common stock. F5: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho.
F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).
F3: Vested in full.
F4: Each restricted stock unit represents the right to receive one share of Quidel common stock.
F5: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).
F6: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2019 Filed May 16, 2019 19:34 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Equity Grant) · Derivative | 2,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-030642 · doc4.xml · derivative · entry 4 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,100 Underlying: Common Stock · 2,100 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F5 · derivative.exercise_date: The restricted stock units vest on May 14, 2020. F5 · derivative.expiration_date: The restricted stock units vest on May 14, 2020. Read SEC document |
| May 14, 2019 Filed May 16, 2019 19:34 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Premium) · Derivative | 315 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-030642 · doc4.xml · derivative · entry 3 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315 Underlying: Common Stock · 315 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F5 · derivative.exercise_date: The restricted stock units vest on May 14, 2020. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F5 · derivative.expiration_date: The restricted stock units vest on May 14, 2020. Read SEC document |
| May 14, 2019 Filed May 16, 2019 19:34 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Converted) · Derivative | 1,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-030642 · doc4.xml · derivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,050 Underlying: Common Stock · 1,050 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F4 · derivative.exercise_date: The restricted stock units vest on the date of the grant, May 14, 2019. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F4 · derivative.expiration_date: The restricted stock units vest on the date of the grant, May 14, 2019. Read SEC document |
| May 02, 2019 Filed May 3, 2019 22:17 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001209191-19-027534 · doc4.xml · derivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2029-05-01 F1 · derivative.exercise_date: The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant (5/2/2020), subject to the reporting person's continued service to the Issuer through such vesting date. Read SEC document |
| May 17, 2018 Filed May 17, 2018 20:17 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionCommon Stock | 2,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-031233 · doc4.xml · nonDerivative · entry 3 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,655 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects vesting of prior restricted stock units, which were previously reported on a Form 4. Read SEC document |
| May 17, 2018 Filed May 17, 2018 20:17 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionCommon Stock | 510 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-031233 · doc4.xml · nonDerivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects vesting of prior restricted stock units, which were previously reported on a Form 4. Read SEC document |
| May 16, 2018 Filed May 17, 2018 20:17 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionCommon Stock | 2,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-031233 · doc4.xml · nonDerivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects vesting of prior restricted stock units, which were previously reported on a Form 4. Read SEC document |
| May 15, 2018 Filed May 17, 2018 20:17 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Equity Grant) · Derivative | 1,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-031233 · doc4.xml · derivative · entry 6 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,661 Underlying: Common Stock · 1,661 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common Stock. F5 · derivative.exercise_date: The restricted stock units vest on May 15, 2019. F5 · derivative.expiration_date: The restricted stock units vest on May 15, 2019. Read SEC document |
| May 15, 2018 Filed May 17, 2018 20:17 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Premium) · Derivative | 237 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-031233 · doc4.xml · derivative · entry 5 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237 Underlying: Common Stock · 237 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common Stock. F3 · shares: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F5 · derivative.exercise_date: The restricted stock units vest on May 15, 2019. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F5 · derivative.expiration_date: The restricted stock units vest on May 15, 2019. Read SEC document |
| May 15, 2018 Filed May 17, 2018 20:17 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Converted) · Derivative | 791 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-031233 · doc4.xml · derivative · entry 4 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 791 Underlying: Common Stock · 791 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common Stock. F3 · shares: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F4 · derivative.exercise_date: The restricted stock units vest on the date of grant, May 15, 2018. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F4 · derivative.expiration_date: The restricted stock units vest on the date of grant, May 15, 2018. Read SEC document |
| April 26, 2018 Filed Apr 27, 2018 20:34 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001209191-18-026595 · doc4.xml · derivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2028-04-25 F1 · derivative.exercise_date: The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant (4/26/2019), subject to the reporting person's continued service to the Issuer through such vesting date. Read SEC document |
| November 06, 2017 Filed Nov 8, 2017 20:28 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GiftCommon Stock | 530 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-059866 · doc4.xml · nonDerivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,680 F1 · price: Shares transferred as a bona fide gift. Read SEC document |
| May 17, 2017 Filed May 18, 2017 20:11 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionCommon Stock | 962 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033757 · doc4.xml · nonDerivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Reflects vesting of prior restricted stock units, which were previously reported on a Form 4. Read SEC document |
| May 16, 2017 Filed May 18, 2017 20:11 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantNon-Qualified Stock Options · Derivative | 5,065 | $0.00 Strike: $24.80 | $0.00 |
DisclosureSEC source: 0001209191-17-033757 · doc4.xml · derivative · entry 5 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,065 Underlying: Common Stock · 5,065 shares Expires 2027-05-16 Read SEC document |
| May 16, 2017 Filed May 18, 2017 20:11 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Equity Grant) · Derivative | 2,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033757 · doc4.xml · derivative · entry 4 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,016 Underlying: Common Stock · 2,016 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F5 · derivative.exercise_date: The restricted stock units vest on the first anniversary date of the grant date, May 16, 2018. F5 · derivative.expiration_date: The restricted stock units vest on the first anniversary date of the grant date, May 16, 2018. Read SEC document |
| May 16, 2017 Filed May 18, 2017 20:11 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Premium) · Derivative | 606 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033757 · doc4.xml · derivative · entry 3 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 606 Underlying: Common Stock · 606 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F4 · shares: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a 2017 compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F4 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a 2017 compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F5 · derivative.exercise_date: The restricted stock units vest on the first anniversary date of the grant date, May 16, 2018. F4 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a 2017 compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F5 · derivative.expiration_date: The restricted stock units vest on the first anniversary date of the grant date, May 16, 2018. Read SEC document |
| May 16, 2017 Filed May 18, 2017 20:11 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantCommon Stock | 2,022 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033757 · doc4.xml · nonDerivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,248 F1 · shares: The reporting person has received a fully vested stock payment award for shares of the Company's common stock in lieu of cash payments for certain retainer and Board of Director service-related fees under a 2017 compensation program applicable to participating non-employee directors. Read SEC document |
| May 05, 2017 Filed May 9, 2017 20:30 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionCommon Stock | 351 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-031113 · doc4.xml · nonDerivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,226 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects vesting of prior restricted stock units, which were previously reported on a Form 4. Read SEC document |
| May 05, 2017 Filed May 9, 2017 20:30 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionCommon Stock | 1,756 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-031113 · doc4.xml · nonDerivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects vesting of prior restricted stock units, which were previously reported on a Form 4. Read SEC document |
| May 03, 2017 Filed May 5, 2017 22:04 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001209191-17-030437 · doc4.xml · derivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2027-05-02 F1 · derivative.exercise_date: The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant (5/3/2018), subject to the reporting person's continued service to the Issuer through such vesting date. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 22:07 UTC | Evoke Pharma Inc EVOK · Entity 71094 | PurchaseCommon Stock | 10,465 | $2.90 | $30,348.50 |
DisclosureSEC source: 0001209191-17-014418 · doc4.xml · nonDerivative · entry 3 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by Partners Disclosed balance after: 36,821 F1 · ownership.nature: The reported securities are owned directly by each of LVPMC, LLC ("LVPMC"), LVP Life Science Ventures III, L.P. ("LVP III"), LVP III Associates, L.P. ("Associates") and LVP III Partners, L.P. ("Partners"). LVP GP III, LLC ("GP III") is the general partner of LVP III, Associates and Partners. The reporting person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 22:07 UTC | Evoke Pharma Inc EVOK · Entity 71094 | PurchaseCommon Stock | 20,930 | $2.90 | $60,697.00 |
DisclosureSEC source: 0001209191-17-014418 · doc4.xml · nonDerivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by Associates Disclosed balance after: 73,641 F1 · ownership.nature: The reported securities are owned directly by each of LVPMC, LLC ("LVPMC"), LVP Life Science Ventures III, L.P. ("LVP III"), LVP III Associates, L.P. ("Associates") and LVP III Partners, L.P. ("Partners"). LVP GP III, LLC ("GP III") is the general partner of LVP III, Associates and Partners. The reporting person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 22:07 UTC | Evoke Pharma Inc EVOK · Entity 71094 | PurchaseCommon Stock | 418,605 | $2.90 | $1,213,954.50 |
DisclosureSEC source: 0001209191-17-014418 · doc4.xml · nonDerivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by LVP III Disclosed balance after: 1,472,867 F1 · ownership.nature: The reported securities are owned directly by each of LVPMC, LLC ("LVPMC"), LVP Life Science Ventures III, L.P. ("LVP III"), LVP III Associates, L.P. ("Associates") and LVP III Partners, L.P. ("Partners"). LVP GP III, LLC ("GP III") is the general partner of LVP III, Associates and Partners. The reporting person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.